Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Cost of Revenue (2023 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Cost of Revenue for 3 consecutive years, with $115000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue fell 98.49% year-over-year to $115000.0, compared with a TTM value of $27.9 million through Sep 2025, up 60.6%, and an annual FY2024 reading of $21.0 million, up 136.43% over the prior year.
  • Cost of Revenue was $115000.0 for Q3 2025 at Atara Biotherapeutics, down from $554000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $20.4 million in Q1 2025 and bottomed at $115000.0 in Q3 2025.
  • Average Cost of Revenue over 3 years is $4.6 million, with a median of $2.9 million recorded in 2023.
  • Peak annual rise in Cost of Revenue hit 929.67% in 2025, while the deepest fall reached 98.49% in 2025.
  • Year by year, Cost of Revenue stood at $3.2 million in 2023, then skyrocketed by 115.03% to $6.8 million in 2024, then crashed by 98.31% to $115000.0 in 2025.
  • Business Quant data shows Cost of Revenue for ATRA at $115000.0 in Q3 2025, $554000.0 in Q2 2025, and $20.4 million in Q1 2025.